Abrdn Life Sciences Investors (NYSE:HQL) Shares Acquired by Needham Investment Management LLC

Needham Investment Management LLC increased its position in shares of Abrdn Life Sciences Investors (NYSE:HQL) by 3.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 352,719 shares of the company’s stock after buying an additional 10,904 shares during the period. Needham Investment Management LLC’s holdings in Abrdn Life Sciences Investors were worth $5,319,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Penserra Capital Management LLC purchased a new stake in shares of Abrdn Life Sciences Investors during the third quarter worth approximately $11,702,000. Cetera Investment Advisers increased its stake in Abrdn Life Sciences Investors by 6.9% in the second quarter. Cetera Investment Advisers now owns 156,384 shares of the company’s stock valued at $2,216,000 after purchasing an additional 10,137 shares during the last quarter. Cetera Advisors LLC purchased a new position in Abrdn Life Sciences Investors in the first quarter valued at approximately $1,929,000. 180 Wealth Advisors LLC increased its stake in Abrdn Life Sciences Investors by 2.8% in the second quarter. 180 Wealth Advisors LLC now owns 136,231 shares of the company’s stock valued at $2,013,000 after purchasing an additional 3,682 shares during the last quarter. Finally, Blue Bell Private Wealth Management LLC increased its stake in Abrdn Life Sciences Investors by 97.6% in the second quarter. Blue Bell Private Wealth Management LLC now owns 62,244 shares of the company’s stock valued at $882,000 after purchasing an additional 30,750 shares during the last quarter. 32.21% of the stock is currently owned by hedge funds and other institutional investors.

Abrdn Life Sciences Investors Stock Performance

Abrdn Life Sciences Investors stock traded up $0.15 during mid-day trading on Tuesday, hitting $14.44. The company had a trading volume of 16,765 shares, compared to its average volume of 92,573. Abrdn Life Sciences Investors has a 1 year low of $12.05 and a 1 year high of $15.90. The business has a fifty day moving average of $14.74 and a 200 day moving average of $14.68.

Abrdn Life Sciences Investors Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Thursday, November 21st will be paid a $0.50 dividend. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. This represents a $2.00 annualized dividend and a yield of 13.85%. The ex-dividend date of this dividend is Thursday, November 21st.

Abrdn Life Sciences Investors Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.